Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

  		Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors
Colby drugs resore therapy-sensitivity or normoxia

About Colby

Scientific Advisory Board

 

Colby's Scientific Advisory Board (SAB) includes  thought leaders in chemistry, oncology, hypoxia and therapy-sistance The members of SAB were instrumental to Colby's drug candidate and drug discovery platform development and are actively engaged in shaping both pre-clinical and clinical drug development.